22 results on '"Jennifer H. Gunter"'
Search Results
2. TGFβ and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity
- Author
-
Fernando Souza-Fonseca-Guimaraes, Gustavo R. Rossi, Laura F. Dagley, Momeneh Foroutan, Timothy R. McCulloch, Jumana Yousef, Hae-Young Park, Jennifer H. Gunter, Paul A. Beavis, Cheng-Yu Lin, Soroor Hediyeh-Zadeh, Tania Camilleri, Melissa J. Davis, and Nicholas D. Huntington
- Subjects
Interleukin-15 ,Killer Cells, Natural ,Cancer Research ,Mice ,Transforming Growth Factor beta ,Cell Line, Tumor ,Neoplasms ,Immunology ,Tumor Microenvironment ,Animals - Abstract
Antibodies targeting “immune checkpoints” have revolutionized cancer therapy by reactivating tumor-resident cytotoxic lymphocytes, primarily CD8+ T cells. Interest in targeting analogous pathways in other cytotoxic lymphocytes is growing. Natural killer (NK) cells are key to cancer immunosurveillance by eradicating metastases and driving solid tumor inflammation. NK-cell antitumor function is dependent on the cytokine IL15. Ablation of the IL15 signaling inhibitor CIS (Cish) enhances NK-cell antitumor immunity by increasing NK-cell metabolism and persistence within the tumor microenvironment (TME). The TME has also been shown to impair NK-cell fitness via the production of immunosuppressive transforming growth factor β (TGFβ), a suppression which occurs even in the presence of high IL15 signaling. Here, we identified an unexpected interaction between CIS and the TGFβ signaling pathway in NK cells. Independently, Cish- and Tgfbr2-deficient NK cells are both hyperresponsive to IL15 and hyporesponsive to TGFβ, with dramatically enhanced antitumor immunity. Remarkably, when both these immunosuppressive genes are simultaneously deleted in NK cells, mice are largely resistant to tumor development, suggesting that combining suppression of these two pathways might represent a novel therapeutic strategy to enhance innate anticancer immunity.
- Published
- 2021
3. Allele-Specific MicroRNA-Mediated Regulation of a Glycolysis Gatekeeper PDK1 in Cancer Metabolism
- Author
-
Sugarniya Subramaniam, Jyotsna Batra, Jennifer H. Gunter, Varinder Jeet, and Judith A. Clements
- Subjects
0301 basic medicine ,Cancer Research ,Reporter gene ,Gene knockdown ,Pyruvate dehydrogenase kinase ,animal structures ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Single-nucleotide polymorphism ,MiRNA binding ,Biology ,Molecular biology ,Article ,microRNAs ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,PDK1 ,030220 oncology & carcinogenesis ,microRNA ,single-nucleotide polymorphisms ,metabolic reprogramming ,Allele ,Gene ,RC254-282 - Abstract
Background: Emerging evidence has revealed that genetic variations in microRNA (miRNA) binding sites called miRSNPs can alter miRNA binding in an allele-specific manner and impart prostate cancer (PCa) risk. Two miRSNPs, rs1530865 (G >, C) and rs2357637 (C >, A), in the 3′ untranslated region of pyruvate dehydrogenase kinase 1 (PDK1) have been previously reported to be associated with PCa risk. However, these results have not been functionally validated. Methods: In silico analysis was used to predict miRNA–PDK1 interactions and was tested using PDK1 knockdown, miRNA overexpression and reporter gene assay. Results: PDK1 expression was found to be upregulated in PCa metastasis. Further, our results show that PDK1 suppression reduced the migration, invasion, and glycolysis of PCa cells. Computational predictions showed that miR-3916, miR-3125 and miR-3928 had a higher binding affinity for the C allele than the G allele for the rs1530865 miRSNP which was validated by reporter gene assays. Similarly, miR-2116 and miR-889 had a higher affinity for the A than C allele of the rs2357637 miRSNP. Overexpression of miR-3916 and miR-3125 decreased PDK1 protein levels in cells expressing the rs1530865 SNP C allele, and miR-2116 reduced in cells with the rs2357637 SNP A allele. Conclusions: The present study is the first to report the regulation of the PDK1 gene by miRNAs in an allele-dependent manner and highlights the role of PDK1 in metabolic adaption associated with PCa progression.
- Published
- 2021
4. Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer
- Author
-
Samantha J. Stehbens, Leisl M. Packer, Robert J. Ju, Jennifer H. Gunter, Michael Gartside, Pamela M. Pollock, Micheal S. Ward, Vanessa F. Bonazzi, and Sara A. Byron
- Subjects
0301 basic medicine ,Cancer Research ,Apoptosis ,Mice ,0302 clinical medicine ,Research Articles ,FGFR2 inhibitor ,General Medicine ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Mitochondria ,3. Good health ,cell death ,Proto-Oncogene Proteins c-bcl-2 ,Oncology ,Fibroblast growth factor receptor ,Caspases ,030220 oncology & carcinogenesis ,embryonic structures ,endometrial cancer ,Molecular Medicine ,Female ,biological phenomena, cell phenomena, and immunity ,Research Article ,Programmed cell death ,FGFR Inhibition ,lcsh:RC254-282 ,ABT263 ,Inhibitory Concentration 50 ,03 medical and health sciences ,In vivo ,BGJ398 ,Cell Line, Tumor ,Genetics ,medicine ,Animals ,Humans ,Receptor, Fibroblast Growth Factor, Type 2 ,Fibroblast growth factor receptor 2 ,business.industry ,Endometrial cancer ,Autophagosomes ,Cancer ,medicine.disease ,Endometrial Neoplasms ,Enzyme Activation ,030104 developmental biology ,Cell culture ,Mutation ,Cancer research ,business - Abstract
Endometrial cancer is the most commonly diagnosed gynaecological malignancy. Unfortunately, 15-20% of women demonstrate persistent or recurrent tumours that are refractory to current chemotherapies. We previously identified activating mutations in fibroblast growth factor receptor 2 (FGFR2) in 12% (stage I/II) to 17% (stage III/IV) endometrioid ECs and found that these mutations are associated with shorter progression-free and cancer-specific survival. Although FGFR inhibitors are undergoing clinical trials for treatment of several cancer types, little is known about the mechanism by which they induce cell death. We show that treatment with BGJ398, AZD4547 and PD173074 causes mitochondrial depolarization, cytochrome c release and impaired mitochondrial respiration in two FGFR2-mutant EC cell lines (AN3CA and JHUEM2). Despite this mitochondrial dysfunction, we were unable to detect caspase activation following FGFR inhibition; in addition, the pan-caspase inhibitor Z-VAD-FMK was unable to prevent cell death, suggesting that the cell death is caspase-independent. Furthermore, while FGFR inhibition led to an increase in LC3 puncta, treatment with bafilomycin did not further increase lipidated LC3, suggesting that FGFR inhibition led to a block in autophagosome degradation. We confirmed that cell death is mitochondrial-dependent as it can be blocked by overexpression of Bcl-2 and/or Bcl-XL. Importantly, we show that combining FGFR inhibitors with the BH3 mimetics ABT737/ABT263 markedly increased cell death in vitro and is more effective than BGJ398 alone in vivo, where it leads to marked tumour regression. This work may have implications for the design of clinical trials to treat a wide range of patients with FGFR-dependent malignancies.
- Published
- 2019
5. Leptin antagonism inhibits prostate cancer xenograft growth and progression
- Author
-
Charles L. Bidgood, Michelle S. Libério, Martin C. Sadowski, Melanie Lehman, Colleen C. Nelson, John D. Wade, Jennifer H. Gunter, Lisa Philp, Anja Rockstroh, Stephen McPherson, Laszlo Otvos, Gregor Tevz, Nenad Bartonicek, and Atefeh Taherian Fard
- Subjects
Leptin ,Male ,0301 basic medicine ,Cancer Research ,medicine.drug_class ,Angiogenesis ,Endocrinology, Diabetes and Metabolism ,Adipokine ,610 Medicine & health ,urologic and male genital diseases ,Androgen deprivation therapy ,Mice ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Endocrinology ,Cell Line, Tumor ,LNCaP ,Animals ,Humans ,Medicine ,Leptin receptor ,business.industry ,Prostatic Neoplasms ,Androgen Antagonists ,medicine.disease ,Androgen ,Prostatic Neoplasms, Castration-Resistant ,030104 developmental biology ,Oncology ,Receptors, Androgen ,030220 oncology & carcinogenesis ,Androgens ,Cancer research ,Heterografts ,570 Life sciences ,biology ,business - Abstract
Hyperleptinaemia is a well-established therapeutic side effect of drugs inhibiting the androgen axis in prostate cancer (PCa), including main stay androgen deprivation therapy (ADT) and androgen targeted therapies (ATT). Given significant crossover between the adipokine hormone signalling of leptin and multiple cancer-promoting hallmark pathways, including growth, proliferation, migration, angiogenesis, metabolism and inflammation, targeting the leptin axis is therapeutically appealing, especially in advanced PCa where current therapies fail to be curative. In this study, we uncover leptin as a novel universal target in PCa and are the first to highlight increased intratumoural leptin and leptin receptor (LEPR) expression in PCa cells and patients' tumours exposed to androgen deprivation, as is observed in patients' tumours of metastatic and castrate resistant (CRPC) PCa. We also reveal the world-first preclinical evidence that demonstrates marked efficacy of targeted leptin-signalling blockade, using Allo-aca, a potent, specific, and safe LEPR peptide antagonist. Allo-aca-suppressed tumour growth and delayed progression to CRPC in mice bearing LNCaP xenografts, with reduced tumour vascularity and altered pathways of apoptosis, transcription/translation, and energetics in tumours determined as potential mechanisms underpinning anti-tumour efficacy. We highlight LEPR blockade in combination with androgen axis inhibition represents a promising new therapeutic strategy vital in advanced PCa treatment.
- Published
- 2021
6. The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype
- Author
-
Elizabeth D. Williams, Lidija Jovanovic, Jennifer H. Gunter, Carina Walpole, Adrian C. Herington, Colleen C. Nelson, Eliza Whiteside, Patrick Thomas, Inge Seim, Manuel D. Gahete, Raúl M. Luque, Michelle Maugham, Penny L. Jeffery, Lisa K. Chopin, and Rakesh N. Veedu
- Subjects
lcsh:Medicine ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Transcriptome ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,lncRNA ,DU145 ,LNCaP ,medicine ,Molecular Biology ,030304 developmental biology ,0303 health sciences ,General Neuroscience ,lcsh:R ,Cancer ,Tumour growth ,Cell Biology ,General Medicine ,medicine.disease ,Long non-coding RNA ,3. Good health ,Androgen receptor ,Antisense transcript ,Tumor progression ,030220 oncology & carcinogenesis ,Cancer research ,Gene expression ,General Agricultural and Biological Sciences - Abstract
It is now appreciated that long non-coding RNAs (lncRNAs) are important players in the orchestration of cancer progression. In this study we characterizedGHSROS, a human lncRNA gene on the opposite DNA strand (antisense) to the ghrelin receptor gene, in prostate cancer. The lncRNA was upregulated by prostate tumors from different clinical datasets. Consistently, transcriptome data revealed thatGHSROSalters the expression of cancer-associated genes. Functional analysesin vitroshowed thatGHSROSmediates tumor growth, migration, and survival and resistance to the cytotoxic drug docetaxel. Increased cellular proliferation ofGHSROS-overexpressing PC3, DU145, and LNCaP prostate cancer cell linesin vitrowas recapitulated in a subcutaneous xenograft model. Conversely,in vitroantisense oligonucleotide inhibition of the lncRNA reciprocally regulated cell growth and migration, and gene expression. Notably,GHSROSmodulates the expression of PPP2R2C, the loss of which may drive androgen receptor pathway-independent prostate tumor progression in a subset of prostate cancers. Collectively, our findings suggest thatGHSROScan reprogram prostate cancer cells toward a more aggressive phenotype and that this lncRNA may represent a potential therapeutic target.
- Published
- 2021
7. Revisiting Glycogen in Cancer: A Conspicuous and Targetable Enabler of Malignant Transformation
- Author
-
Thomas Kryza, Jennifer H. Gunter, Mitchell A. Sullivan, Nicholas Lyons, Tashbib Khan, Yaowu He, and John D. Hooper
- Subjects
0301 basic medicine ,Cancer Research ,Mini Review ,immunometabolism ,Cell ,cancer metabolism ,Malignancy ,lcsh:RC254-282 ,Malignant transformation ,Metastasis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Immune system ,medicine ,metabolic reprogramming ,Tumor microenvironment ,Glycogen ,business.industry ,chemoresistance ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,chemistry ,glycogen ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,cancer therapy ,business - Abstract
Once thought to be exclusively a storage hub for glucose, glycogen is now known to be essential in a range of physiological processes and pathological conditions. Glycogen lies at the nexus of diverse processes that promote malignancy, including proliferation, migration, invasion, and chemoresistance of cancer cells. It is also implicated in processes associated with the tumor microenvironment such as immune cell effector function and crosstalk with cancer-associated fibroblasts to promote metastasis. The enzymes of glycogen metabolism are dysregulated in a wide variety of malignancies, including cancers of the kidney, ovary, lung, bladder, liver, blood, and breast. Understanding and targeting glycogen metabolism in cancer presents a promising but under-explored therapeutic avenue. In this review, we summarize the current literature on the role of glycogen in cancer progression and discuss its potential as a therapeutic target for cancer treatment.
- Published
- 2020
8. Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma
- Author
-
Thomas McGann, Nisha Jagasia, Josephine M. Forbes, T. Cuda, Jermaine Coward, Andy Wu, Thomas Kryza, Paul Haluska, John D. Hooper, Naven Chetty, Brittney S. Harrington, Lewis Perrin, Sinead Barry, Tashbib Khan, Amy Broomfield, Cameron Snell, Jennifer H. Gunter, Rebecca Rogers, S. John Weroha, Rohan Lourie, Jane E. Armes, Claire M. Davies, Mitchell A. Sullivan, Yaowu He, and Madeline Gough
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_treatment ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Medicine ,Clear-cell ovarian carcinoma ,Adverse effect ,Chemotherapy ,Glycogen ,clear cell ovarian cancer ,business.industry ,Cancer ,2DG ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Carboplatin ,Clinical trial ,030104 developmental biology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,glycogen ,Clear cell carcinoma ,Cancer research ,business - Abstract
High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses&mdash, of more than 10-fold lower than previously reported for other cancers&mdash, significantly improve the efficacy of carboplatin against cell line and patient-derived xenograft models in mice that mimic the chemo-responsiveness of OCC. These findings are encouraging, in that 2DG doses, which are substantially lower than previously reported to cause adverse events in cancer patients, can safely and significantly improve the efficacy of carboplatin against OCC. Our results thus justify clinical trials to evaluate whether low dose 2DG improves the efficacy of carboplatin in OCC patients.
- Published
- 2020
- Full Text
- View/download PDF
9. A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome
- Author
-
Ralph Buttyan, Brett G. Hollier, Jennifer H. Gunter, Martin C. Sadowski, Chenwei Wang, Abhishek S. Kashyap, Martin E. Gleave, Colleen C. Nelson, Elizabeth D. Williams, Nataly Stylianou, Anja Rockstroh, Atefeh Taherian Fard, Micheal S. Ward, Melanie Lehman, Lidija Jovanovic, Thomas F. Westbrook, and Ladan Fazli
- Subjects
0301 basic medicine ,Cancer Research ,Mesenchymal stem cell ,Cancer ,Biology ,Gene signature ,medicine.disease ,Phenotype ,3. Good health ,03 medical and health sciences ,Prostate cancer ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Cancer cell ,Genetics ,Cancer research ,medicine ,Carcinoma ,Epithelial–mesenchymal transition ,Molecular Biology - Abstract
The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial–mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations using reversible models of EMT, revealed the mesenchymal-to-epithelial reverting transition (MErT) to be enriched in clinical samples of metastatic castrate resistant prostate cancer (mCRPC). From this enrichment, a metastasis-derived gene signature was identified that predicted more rapid cancer relapse and reduced survival across multiple human carcinoma types. Additionally, the transcriptional profile of MErT is not a simple mirror image of EMT as tumour cells retain a transcriptional “memory” following a reversible EMT. This memory was also enriched in mCRPC samples. Cumulatively, our studies reveal the transcriptional profile of epithelial–mesenchymal plasticity and highlight the unique transcriptional properties of MErT. Furthermore, our findings provide evidence to support the association of epithelial plasticity with poor clinical outcomes in multiple human carcinoma types.
- Published
- 2018
10. Abstract 996: Cold atmospheric plasma therapy selectively targets triple negative breast cancer cells
- Author
-
Kostya Ostrikov, Xiaofeng Dai, Derek Richard, Renwu Zhou, Jennifer H. Gunter, Fiona Simpson, Erik Rik Walter Thompson, Peiyu Wang, and Rusen Zhou
- Subjects
Cancer Research ,Chemistry ,medicine.disease ,Breast cancer ,Oncology ,Apoptosis ,Cell culture ,Cancer cell ,Cancer research ,medicine ,Cytotoxic T cell ,Hormonal therapy ,Viability assay ,Triple-negative breast cancer - Abstract
Background: Cancer cells notoriously escape radiation therapy, chemotherapy, hormonal therapy, and other anti-cancer therapies. Among various breast cancer subtypes, triple negative breast cancers (TNBCs) are known for their poor clinical outcome and dearth of effective targeted therapies due to the absence of druggable receptors. Cold atmospheric plasma (CAP) holds promise as a cancer-specific treatment agent that selectively kills basal-like/TN breast cancer cells. Method: In this study, we used plasma-activated media (PAM) to capture and store the multi-modal chemical species of CAP, which significantly expands the treatment scope and flexibility of plasma medicine as a clinical therapeutic approach. The PAM was diluted into different doses and cells were treated for 12 or 24 hours. The effects of PAM on cell viability and ROS levels in 9 different cell lines; normal cells (MCF-10A and HEK-293T), luminal breast cancer cell lines (MCF-7, T47D, HCC70), and TNBC cell lines (MDA-MB-468, SUM-159PT, SUM-149PT, MDA-MB-231), were assessed. Results: The results showed that TNBC cells were more highly sensitive, in a dose-dependent manner, to PAM treatment. PAM selectively caused apoptosis of TNBC cell lines compared to luminal lines and had little effect on the normal cell lines. It has been hypothesised that the cancer-selective CAP and PAM cytotoxicity is due in part to reactive oxygen (ROS) and nitrogen species (RNS). Constitutive RONS levels, combined with those present in and/or induced by PAM, can combine to push the cells over a cytotoxic threshold. In support of this, we found a tight correlation (R2=0.7502) between the constitutive ROS level of different cell lines used and their response (cell viability) to 100% PAM treatment, and found that ROS levels selectively increased further in the TNBC>luminal>normal cells in response to PAM. We have also identified a strong synergistic molecular partner that further promotes sensitivity and selectivity of PAM for TNBC cells. Conclusion: We demonstrated that treatment with PAM promotes apoptosis n cell lines representing the most aggressive TNBC subtype. This discovery opens new TNBC-selective opportunities for simultaneous inhibition of diverse (parallel) cancer development factors through synergistic interactions enabled through plasma activated biochemical media. Citation Format: Peiyu Wang, Renwu Zhou, Rusen Zhou, Jennifer Gunter, Fiona Simpson, Kostya (Ken) Ostrikov, Derek Richard, Xiaofeng Dai, Erik (Rik) Walter Thompson. Cold atmospheric plasma therapy selectively targets triple negative breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 996.
- Published
- 2021
11. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
- Author
-
Elizabeth D. Williams, K McGowan, Miriam S. Butler, Jennifer H. Gunter, Ellca Ratther, Pamela J. Russell, N. Erho, Mohammed Alshalafa, Melanie Lehman, Mannan Nouri, Edward M. Schaeffer, Ladan Fazli, Robert Jeffrey Karnes, P S Rennie, Ashley E. Ross, Brett G. Hollier, Stephen McPherson, Nataly Stylianou, Rajdeep Das, Ralph Buttyan, Philip A. Gregory, Jacqui A. McGovern, Josselin Caradec, Luke A. Selth, E. Davicioni, Brian W.C. Tse, Marianna Volpert, Robert B. Jenkins, Robert B. Den, Martin E. Gleave, Colleen C. Nelson, Mani Roshan-Moniri, M. Takhar, Cheryl Y. Gregory-Evans, Tse, BWC, Volpert, M, Ratther, E, Stylianou, N, Gregory, PA, and Hollier, B. G.
- Subjects
Male ,0301 basic medicine ,Biochemical recurrence ,PCA3 ,Cancer Research ,Epithelial-Mesenchymal Transition ,medicine.medical_treatment ,Biology ,androgen-targeted ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Cell Line, Tumor ,Genetics ,medicine ,Humans ,Neoplasm Metastasis ,Molecular Biology ,Tissue microarray ,Prostatic Neoplasms ,metastatic progression ,Cancer ,Androgen Antagonists ,medicine.disease ,Survival Analysis ,prostate tumors ,Neuropilin-1 ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Radiation therapy ,Prostatic Neoplasms, Castration-Resistant ,030104 developmental biology ,Tumor progression ,030220 oncology & carcinogenesis ,Immunology ,Disease Progression ,Cancer research ,Original Article ,Neoplasm Grading ,patient mortality - Abstract
Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa. Refereed/Peer-reviewed
- Published
- 2017
12. A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer progression
- Author
-
AS Kashyap, Nataly Stylianou, Martin E. Gleave, Colleen C. Nelson, TF Westbrook, Anja Rockstroh, Brett G. Hollier, MC Sadowski, AT Fard, Melanie Lehman, Elizabeth D. Williams, R Buttyan, Ladan Fazli, C Wang, M Ward, Lidija Jovanovic, and Jennifer H. Gunter
- Subjects
Prostate cancer ,business.industry ,Cancer research ,Medicine ,Epithelial mesenchymal plasticity ,General Medicine ,business ,medicine.disease - Published
- 2019
13. Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2
- Author
-
Wendy Lee, Phoebe Sarkar, Melanie Lehman, Jennifer H. Gunter, Elizabeth D. Williams, Ali Shokoohmand, Colleen C. Nelson, Nataly Stylianou, Amy A. Lubik, and Brett G. Hollier
- Subjects
0301 basic medicine ,androgen deprivation ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,urologic and male genital diseases ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Androgen deprivation therapy ,03 medical and health sciences ,Prostate cancer ,Endocrinology ,0302 clinical medicine ,DU145 ,Downregulation and upregulation ,LNCaP ,medicine ,epithelial to mesenchymal transition (EMT) ,Epithelial–mesenchymal transition ,Original Research ,lcsh:RC648-665 ,biology ,business.industry ,medicine.disease ,prostate cancer ,invasion ,Insulin receptor ,030104 developmental biology ,Cancer cell ,hyperinsulinemia ,biology.protein ,Cancer research ,FOXC2 ,business - Abstract
Androgen deprivation therapy (ADT) is the standard treatment for advanced prostate cancer (PCa), yet many patients relapse with lethal metastatic disease. With this loss of androgens, increased cell plasticity has been observed as an adaptive response to ADT. This includes gain of invasive and migratory capabilities, which may contribute to PCa metastasis. Hyperinsulinemia, which develops as a side-effect of ADT, has been associated with increased tumor aggressiveness and faster treatment failure. We investigated the direct effects of insulin in PCa cells that may contribute to this progression. We measured cell migration and invasion induced by insulin using wound healing and transwell assays in a range of PCa cell lines of variable androgen dependency (LNCaP, 22RV1, DuCaP, and DU145 cell lines). To determine the molecular events driving insulin-induced invasion we used transcriptomics, quantitative real time-PCR, and immunoblotting in three PCa cell lines. Insulin increased invasiveness of PCa cells, upregulating Forkhead Box Protein C2 (FOXC2), and activating key PCa cell plasticity mechanisms including gene changes consistent with epithelial-to-mesenchymal transition (EMT) and a neuroendocrine phenotype. Additionally, analysis of publicly available clinical PCa tumor data showed metastatic prostate tumors demonstrate a positive correlation between insulin receptor expression and the EMT transcription factor FOXC2. The insulin receptor is not suitable to target clinically however, our data shows that actions of insulin in PCa cells may be suppressed by inhibiting downstream signaling molecules, PI3K and ERK1/2. This study identifies for the first time, a mechanism for insulin-driven cancer cell motility and supports the concept that targeting insulin signaling at the level of the PCa tumor may extend the therapeutic efficacy of ADT.
- Published
- 2019
14. Repositioning 'old' drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion
- Author
-
Brett G. Hollier, Tiffany Tang, Esha T. Shah, Akanksha Upadhyaya, Elizabeth D. Williams, Dubravka Skalamera, Lisa Philp, Colleen C. Nelson, and Jennifer H. Gunter
- Subjects
Male ,0301 basic medicine ,Drug ,Cancer Research ,Cell Survival ,media_common.quotation_subject ,Cell ,Antineoplastic Agents ,Pharmacology ,Vandetanib ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,medicine ,Humans ,Neoplasm Invasiveness ,Viability assay ,Neoplasm Metastasis ,media_common ,Drug discovery ,business.industry ,Prostatic Neoplasms ,General Medicine ,medicine.disease ,Drug repositioning ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,business ,medicine.drug - Abstract
The majority of prostate cancer (PCa) deaths occur due to the metastatic spread of tumor cells to distant organs. Currently, there is a lack of effective therapies once tumor cells have spread outside the prostate. It is therefore imperative to rapidly develop therapeutics to inhibit the metastatic spread of tumor cells. Gain of cell motility and invasive properties is the first step of metastasis and by inhibiting motility one can potentially inhibit metastasis. Using the drug repositioning strategy, we developed a cell-based multi-parameter primary screening assay to identify drugs that inhibit the migratory and invasive properties of metastatic PC-3 PCa cells. Following the completion of the primary screening assay, 33 drugs were identified from an FDA approved drug library that either inhibited migration or were cytotoxic to the PC-3 cells. Based on the data obtained from the subsequent validation studies, mitoxantrone hydrochloride, simvastatin, fluvastatin and vandetanib were identified as strong candidates that can inhibit both the migration and invasion of PC-3 cells without significantly affecting cell viability. By employing the drug repositioning strategy instead of a de novo drug discovery and development strategy, the identified drug candidates have the potential to be rapidly translated into the clinic for the management of men with aggressive forms of PCa.
- Published
- 2016
15. Correction: A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome
- Author
-
Micheal S. Ward, Chenwei Wang, Atefeh Taherian Fard, Thomas F. Westbrook, Anja Rockstroh, Martin E. Gleave, Nataly Stylianou, Colleen C. Nelson, Brett G. Hollier, Lidija Jovanovic, Ralph Buttyan, Abhishek S. Kashyap, Jennifer H. Gunter, Ladan Fazli, Elizabeth D. Williams, Martin C. Sadowski, and Melanie Lehman
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Epithelial-Mesenchymal Transition ,Epithelial mesenchymal plasticity ,Biology ,Outcome (game theory) ,Article ,Disease-Free Survival ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Portrait ,Cell Line, Tumor ,Internal medicine ,Genetics ,medicine ,Humans ,Neoplasm Metastasis ,Molecular Biology ,Correction ,medicine.disease ,Survival Rate ,Prostatic Neoplasms, Castration-Resistant ,030104 developmental biology ,030220 oncology & carcinogenesis - Abstract
The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial–mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations using reversible models of EMT, revealed the mesenchymal-to-epithelial reverting transition (MErT) to be enriched in clinical samples of metastatic castrate resistant prostate cancer (mCRPC). From this enrichment, a metastasis-derived gene signature was identified that predicted more rapid cancer relapse and reduced survival across multiple human carcinoma types. Additionally, the transcriptional profile of MErT is not a simple mirror image of EMT as tumour cells retain a transcriptional “memory” following a reversible EMT. This memory was also enriched in mCRPC samples. Cumulatively, our studies reveal the transcriptional profile of epithelial–mesenchymal plasticity and highlight the unique transcriptional properties of MErT. Furthermore, our findings provide evidence to support the association of epithelial plasticity with poor clinical outcomes in multiple human carcinoma types.
- Published
- 2018
16. Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells
- Author
-
Adrian C. Herington, Amy A. Lubik, Jennifer A. Locke, Martin E. Gleave, Colleen C. Nelson, Hans Adomat, Stephen C. Hendy, Vanessa C. Thompson, Jennifer H. Gunter, and Michael Pollak
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Biology ,urologic and male genital diseases ,Gene Expression Regulation, Enzymologic ,Androgen deprivation therapy ,Mice ,Prostate cancer ,Downregulation and upregulation ,Internal medicine ,Insulin receptor substrate ,medicine ,Animals ,Humans ,Insulin ,RNA, Messenger ,Gonadal Steroid Hormones ,Prostatic Neoplasms ,Prostate-Specific Antigen ,medicine.disease ,Xenograft Model Antitumor Assays ,IRS2 ,Gene Expression Regulation, Neoplastic ,Alcohol Oxidoreductases ,Insulin receptor ,Endocrinology ,Oncology ,Protein Biosynthesis ,Dihydrotestosterone ,Androgens ,Insulin Receptor Substrate Proteins ,biology.protein ,medicine.drug - Abstract
Androgen-dependent pathways regulate maintenance and growth of normal and malignant prostate tissues. Androgen deprivation therapy (ADT) exploits this dependence and is used to treat metastatic prostate cancer; however, regression initially seen with ADT gives way to development of incurable castration-resistant prostate cancer (CRPC). Although ADT generates a therapeutic response, it is also associated with a pattern of metabolic alterations consistent with metabolic syndrome including elevated circulating insulin. Because CRPC cells are capable of synthesizing androgens de novo, we hypothesized that insulin may also influence steroidogenesis in CRPC. In this study, we examined this hypothesis by evaluating the effect of insulin on steroid synthesis in prostate cancer cell lines. Treatment with 10 nmol/L insulin increased mRNA and protein expression of steroidogenesis enzymes and upregulated the insulin receptor substrate insulin receptor substrate 2 (IRS-2). Similarly, insulin treatment upregulated intracellular testosterone levels and secreted androgens, with the concentrations of steroids observed similar to the levels reported in prostate cancer patients. With similar potency to dihydrotestosterone, insulin treatment resulted in increased mRNA expression of prostate-specific antigen. CRPC progression also correlated with increased expression of IRS-2 and insulin receptor in vivo. Taken together, our findings support the hypothesis that the elevated insulin levels associated with therapeutic castration may exacerbate progression of prostate cancer to incurable CRPC in part by enhancing steroidogenesis. Cancer Res; 71(17); 5754–64. ©2011 AACR.
- Published
- 2011
17. Abstract 2452: Dysregulated expression of the human long noncoding RNA GHSROS may influence prostate cancer progression and resistance to docetaxel
- Author
-
Patrick Thomas, Eliza Whiteside, Gahete D. Manuel, Raul M Luque, Jennifer H. Gunter, Penny L. Jeffery, Adrian C. Herington, Carina Walpole, Colleen C. Nelson, Inge Seim, Lisa K. Chopin, Michelle Maugham, Rakesh N. Veedu, and Elizabeth D. Williams
- Subjects
Cancer Research ,Prostate cancer ,Oncology ,Docetaxel ,business.industry ,medicine ,Cancer research ,medicine.disease ,business ,medicine.drug - Abstract
Long noncoding RNAs (lncRNAs) play key regulatory roles in cancer progression and are novel therapeutic targets. We recently discovered the lncRNA gene, GHSROS (GHSR opposite strand), on the antisense DNA strand of the ghrelin receptor gene (GHSR). Here, we studied the expression and function of GHSROS in prostate cancer. Interrogation of microarray and RNA-seq data sets revealed that (similar to other lncRNA oncogenes) GHSROS is actively transcribed, although expressed at very low levels in cancer cell lines and tissues. By quantitative RT-PCR we demonstrate that GHSROS is highly expressed in a subset of high-grade prostate cancers (~11.4%). Moreover, the lncRNA is upregulated in high Gleason-score prostate tumors in two clinical data sets. Forced GHSROS overexpression significantly increased in vitro cell proliferation and migration of PC3, DU145, and LNCaP prostate cancer cell lines (P ≤ 0.05, Student's t-test). Increased cell proliferation observed in GHSROS-overexpressing prostate cancer cell lines was recapitulated in PC3, DU145, and LNCaP prostate cancer xenografts in NOD/SCID mice. Cell survival was significantly increased in GHSROS-overexpressing LNCaP cells treated with the cytotoxic drug docetaxel (P ≤ 0.05, Student's t-test). Docetaxel treatment also increased GHSROS expression in native LNCaP and PC3 cells in a dose-dependent manner (P ≤ 0.05, Student's t-test). These data suggest that GHSROS mediates tumor survival and resistance to docetaxel. To identify fundamental drivers of the observed tumorigenic phenotype of GHSROS-overexpressing cell lines, high-throughput RNA-seq data from in vitro cultured PC3 cells and LNCaP xenografts were examined. A quarter of the genes differentially expressed by GHSROS-overexpressing PC3 cells were also differentially expressed by GHSROS-overexpressing LNCaP xenografts. These 101 genes include several transcription factors with established roles in prostate cancer (including the androgen receptor) and genes associated with metastasis and poor prognosis. Finally, we developed two distinct antisense oligonucleotides (ASOs) targeting GHSROS, achieving >60% knockdown, and their function was assessed in vitro. ASO inhibition of GHSROS expression reciprocally regulated cell growth and migration and the expression of a range of genes. These ASOs are currently being assessed in preclinical animal models. Our findings suggest that the long noncoding RNA GHSROS reprograms prostate cancer cells toward a more aggressive phenotype and that the lncRNA represents a promising therapeutic target. Citation Format: Patrick B. Thomas, Penny L. Jeffery, Gahete D. Manuel, Eliza J. Whiteside, Michelle Maugham, Carina Walpole, Jennifer H. Gunter, Elizabeth D. Williams, Colleen C. Nelson, Adrian C. Herington, Raul M. Luque, Rakesh N. Veedu, Lisa K. Chopin, Inge Seim. Dysregulated expression of the human long noncoding RNA GHSROS may influence prostate cancer progression and resistance to docetaxel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2452.
- Published
- 2018
18. Abstract LB-B31: FGFR inhibition in endometrial cancer induces caspase-independent cell death that can be augmented with ABT-737
- Author
-
Samantha J. Stehbens, Leisl M. Packer, David Loch, Andreas Wortmann, Nigel J. Waterhouse, Pamela M. Pollock, Vanessa F. Bonazzi, Mike Gartside, Jennifer H. Gunter, and Sara A. Byron
- Subjects
Cancer Research ,Programmed cell death ,Fibroblast growth factor receptor 2 ,business.industry ,FGFR Inhibition ,Endometrial cancer ,Autophagy ,Cancer ,ENDOG ,Context (language use) ,medicine.disease ,Oncology ,medicine ,Cancer research ,business - Abstract
Endometrial cancer (EC) is the most commonly diagnosed malignancy of the female reproductive tract. Unfortunately, 15-20% of women demonstrate persistent or recurrent tumors that are refractory to current chemotherapies with an associated poor prognosis. Our laboratory identified activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) in 12% (stage I/II) to 17% (stage III/IV) endometrioid endometrial tumors and have since shown in a large (n=970) multi-institutional cohort they are associated with shorter progression free and cancer specific survival. Although FGFR inhibitors are in clinical trials in several cancer types, no detailed study of the mechanism of cell death has been published. We now show that treatment with BGJ398, AZD4547 and PD173074 leads to the induction of mitochondrial depolarization and changes in metabolic flux in two endometrial cancer cell lines (JHUEM2 and AN3CA) carrying activating mutations (C383R and N550K respectively). Despite this mitochondrial dysfunction, we have convincingly shown that the cell death following FGFR inhibition was caspase-independent, as evidenced by the lack of caspase-3, -7, and -9 activation, absence of PARP cleavage, and the inability of the broad-spectrum caspase inhibitor, Z-VAD-FMK, to prevent cell death. Knockdown of EndoG and AIF, common mediators of caspase-independent death, had no effect. Detailed quantification of LC3 positive puncta shows an increase in autophagy in JHUEM2 and AN3CA cells treated with all FGFR inhibitors. Knockdown of ATG3, ATG7 and ATG12 resulted in a slight increase in Annexin positive cell death indicating that the autophagy was cytoprotective in this context. We have now confirmed this novel caspase-independent cell death is mitochondrial dependent as it can be blocked by overexpression of Bcl-2 and/or Bcl-XL. Importantly we have shown that the combination of FGFR inhibitors with the BH3 mimetic ABT737 can markedly augment this caspase-independent cell death which may have implications for the design of more effective clinical trials. Citation Format: Leisl Packer, Sara Byron, Samantha Stehbens, Vanessa Bonazzi, David Loch, Andreas Wortmann, Mike Gartside, Nigel Waterhouse, Jennifer Gunter, Pamela M. Pollock. FGFR inhibition in endometrial cancer induces caspase-independent cell death that can be augmented with ABT-737 [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B31.
- Published
- 2018
19. Abstract 4909: Androgen targeted therapy induces ZEB1 expression and is associated with suppression of androgen signalling and therapy resistance
- Author
-
Gregor Tevz, Atefeh Taherianfard, Melanie Lehman, Elizabeth D. Williams, Ellca Ratther, Nataly Stylianou, Jennifer H. Gunter, Katrina Sweeney, Martin E. Gleave, Colleen C. Nelson, Brett G. Hollier, Akanksha Upadhyaya, and Katrina J Pirlo
- Subjects
Cancer Research ,business.industry ,medicine.drug_class ,medicine.medical_treatment ,Cancer ,urologic and male genital diseases ,medicine.disease ,Androgen ,Targeted therapy ,Metastasis ,Androgen receptor ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,Oncology ,chemistry ,LNCaP ,Cancer research ,Medicine ,030212 general & internal medicine ,Propidium iodide ,business - Abstract
Reactivation of the embryonic developmental pathway, epithelial-to-mesenchymal transition (EMT) is associated with prostate cancer (PCa) metastasis and therapy resistance. Recent evidence has demonstrated EMT is stimulated following androgen targeted therapy (ATT). In the present study we investigated the role of EMT transcription factor ZEB1 in ATT-driven EMT, PCa metastasis and drug resistance. Immunohistochemistry (IHC) staining of ZEB1 on tissue microarrays of primary tumors from clinical samples demonstrated ZEB1 expression correlated with increased tumor aggressiveness and Gleason score. Upon stratification of patient data (n=198), high ZEB1 protein expression correlated with a shorter time to biochemical recurrence (BCR). Furthermore, IHC staining of primary tumours from 148 treatment-naïve patients with and without metastasis demonstrated high ZEB1 levels and correlated to a reduced time to metastasis. To delineate the role of ZEB1 as a molecular driver of late-stage PCa, microarray analysis of an in vivo LNCaP progression model demonstrated ZEB1 levels increased following castration. Significantly, high ZEB1 levels were associated with patients who had undergone neoadjuvant hormone therapy with or without docetaxel and high ZEB1 levels were associated with a shorter time to BCR and metastasis. Inhibition of the androgen/androgen receptor (AR) axis in LNCaP cells using antiandrogen treatment or shRNA targeting AR resulted in upregulation of ZEB1 in LNCaP cells suggesting enhanced levels of ZEB1 may drive the early adaptive response of PCa after hormone therapy. Interestingly, in models where ZEB1 expression was elevated this was accompanied with repression of classical androgen-regulated genes suggesting ZEB1 is able to regulate the AR transcriptional pathway. We also investigated the role of ZEB1 in cancer invasion and chemoresistance. An inducible model of ZEB1 overexpression in LNCaP cells produced a robust EMT upon ZEB1 expression and was accompanied by an invasive phenotype in 3D cultures. ZEB1 overexpression also conferred resistance to docetaxel (IC50 of 8.17±2.45nM in ZEB1-expressing cells vs. 3.35±0.23nM in control cells) potentially as a result of a reduced apoptotic cell death response mediated by ZEB1. At suboptimal doses of docetaxel, the percentage of apoptotic cells (annexin-V+/propidium iodide-) decreased 4-fold when ZEB1 was expressed compared with control cells and was accompanied by a reduction in PARP cleavage and cleaved caspase-7 expression. In summary, we provide evidence that ZEB1 expression is increased in response to ATTs and correlates with disease progression, metastasis and therapy resistance. We also show ZEB1 is a transcriptional regulator of AR signalling in PCa, Together this provides the rationale to target ZEB1 for the development of novel therapies for the treatment of CRPC. Note: This abstract was not presented at the meeting. Citation Format: Katrina G. Sweeney, Nataly Stylianou, Gregor Tevz, Atefeh Taherianfard, Katrina Pirlo, Akanksha Upadhyaya, Ellca Ratther, Melanie Lehman, Martin Gleave, Jennifer Gunter, Elizabeth D. Williams, Colleen C. Nelson, Brett Hollier. Androgen targeted therapy induces ZEB1 expression and is associated with suppression of androgen signalling and therapy resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4909. doi:10.1158/1538-7445.AM2017-4909
- Published
- 2017
20. Abstract 3442: The long non-coding RNA GHSROS mediates expression of genes associated with tumor growth, metastasis and adverse disease outcome
- Author
-
Penny L. Jeffery, Patrick Thomas, Jennifer H. Gunter, Michelle Maugham, Inge Seim, Lidija Jovanovic, Carina Walpole, Rakesh N. Veedu, Lisa K. Chopin, Eliza Whiteside, Adrian C. Herington, and Colleen C. Nelson
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Disease outcome ,Coding (therapy) ,Biology ,medicine.disease ,Metastasis ,Oncology ,Expression (architecture) ,Cancer research ,medicine ,Tumor growth ,Gene - Abstract
Long non-coding RNAs (lncRNAs) play key regulatory roles in cancer progression and are emerging therapeutic targets. The objective of this study was to investigate the expression and function of the lncRNA GHSROS in prostate cancer. Quantitative RT-PCR revealed that GHSROS is highly expressed in a subset of prostate cancers (Gleason score 8-10; z-score >1; Mann-Whitney-Wilcoxon test P=0.0021). Forced overexpression of the lncRNA stimulated cell migration in vitro in the PC3 (1.82 ± 0.35, P=0.006; Student’s t-test), DU145 (1.94 ± 0.34, P=0.017), and LNCaP (1.27 ± 0.02, P=0.0002) prostate cancer cell lines. Cell proliferation was increased in GHSROS overexpressing PC3 (3.36 ± 1.91, P=0.029), DU145 (1.749 ± 0.59, P=0.026), and LNCaP (1.39 ± 0.26, P=0.040) prostate cancer cell lines. These results were recapitulated in NOD/SCID mice, with increased tumor growth and Ki67 immunohistochemical staining in PC3 (P=0.0040) and DU145 (P = 0.036) xenografts overexpressing the lncRNA.High-throughput transcriptome sequencing (RNA-seq) identified 400 differentially expressed genes in GHSROS overexpressing PC3 cells, with enrichment of genes associated with motility, migration and regulation of cell growth. Further interrogation of the 400 gene set using Oncomine concept mapping, and interrogation of publicly-available clinical prostate cancer data sets, revealed a 34-gene signature associated with poorer disease outcome and metastatic progression. Preliminary analysis of The Cancer Genome Atlas (TCGA) data, suggest that the signature has potential as a prognostic indicator for disease free- or overall survival in numerous cancers. Finally, locked antisense oligonucleotide (LNA-ASO) inhibition of endogenous GHSROS reciprocally regulated cell growth (Student’s t-test; RNV124: -1.14 ± 0.06, P=0.049 and RNV104L: -1.18 ± 0.05, P=0.030, migration (RNV124: -1.96 ± 0.11, P=0.004) and gene expression changes, supporting the observations from forced GHSROS overexpression experiments.In summary, we provide evidence that GHSROS is a prostate cancer associated lncRNA that promotes a gene expression signature which enhances the propensity for metastasis and adverse disease outcomes. We also demonstrate that GHSROS can be targeted using antisense oligonucleotides. Further studies on this lncRNA may provide new prognostic and therapeutic opportunities. Citation Format: Patrick B. Thomas, Penny L. Jeffery, Eliza Whiteside, Carina Walpole, Michelle Maugham, Lidija Jovanovic, Jennifer H. Gunter, Colleen C. Nelson, Adrian C. Herington, Rakesh Veedu, Lisa K. Chopin, Inge Seim. The long non-coding RNA GHSROS mediates expression of genes associated with tumor growth, metastasis and adverse disease outcome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3442. doi:10.1158/1538-7445.AM2017-3442
- Published
- 2017
21. IGF2 increases de novo steroidogenesis in prostate cancer cells
- Author
-
Adrian C. Herington, Michael Pollak, Ladan Fazli, Amy A. Lubik, Brett G. Hollier, Martin E. Gleave, Colleen C. Nelson, Stephen C. Hendy, Nataly Stylianou, Susan Ettinger, Jennifer H. Gunter, and Hans Adomat
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,urologic and male genital diseases ,Receptor, IGF Type 2 ,Article ,Androgen deprivation therapy ,Prostate cancer ,Endocrinology ,Insulin-Like Growth Factor II ,Internal medicine ,Insulin receptor substrate ,Cell Line, Tumor ,medicine ,Humans ,RNA, Messenger ,Testosterone ,biology ,Insulin ,Prostatic Neoplasms ,Prostate-Specific Antigen ,medicine.disease ,IRS2 ,Insulin receptor ,Oncology ,Dihydrotestosterone ,biology.protein ,Steroids ,medicine.drug - Abstract
Free to read Androgen-dependent pathways regulate maintenance and growth of normal and malignant prostate tissues. Androgen deprivation therapy (ADT) exploits this dependence and is used to treat metastatic prostate cancer; however, regression initially seen with ADT gives way to development of incurable castration-resistant prostate cancer (CRPC). Although ADT generates a therapeutic response, it is also associated with a pattern of metabolic alterations consistent with metabolic syndrome including elevated circulating insulin. Because CRPC cells are capable of synthesizing androgens de novo, we hypothesized that insulin may also influence steroidogenesis in CRPC. In this study, we examined this hypothesis by evaluating the effect of insulin on steroid synthesis in prostate cancer cell lines. Treatment with 10 nmol/L insulin increased mRNA and protein expression of steroidogenesis enzymes and upregulated the insulin receptor substrate insulin receptor substrate 2 (IRS-2). Similarly, insulin treatment upregulated intracellular testosterone levels and secreted androgens, with the concentrations of steroids observed similar to the levels reported in prostate cancer patients. With similar potency to dihydrotestosterone, insulin treatment resulted in increased mRNA expression of prostate-specific antigen. CRPC progression also correlated with increased expression of IRS-2 and insulin receptor in vivo. Taken together, our findings support the hypothesis that the elevated insulin levels associated with therapeutic castration may exacerbate progression of prostate cancer to incurable CRPC in part by enhancing steroidogenesis.
- Published
- 2013
22. The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
- Author
-
Jennifer H. Gunter, Amy A. Lubik, Colleen C. Nelson, Ian McKenzie, and Michael Pollak
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,Insulin ,medicine.medical_treatment ,Obstetrics and Gynecology ,Review Article ,Disease ,medicine.disease ,lcsh:Diseases of the genitourinary system. Urology ,lcsh:RC870-923 ,Androgen deprivation therapy ,Prostate cancer ,Endocrinology ,medicine.anatomical_structure ,Prostate ,Diabetes mellitus ,Internal medicine ,medicine ,Cancer research ,Metabolic syndrome ,business ,Hormone - Abstract
An association between the metabolic syndrome and reduced testosterone levels has been identified, and a specific inverse relationship between insulin and testosterone levels suggests that an important metabolic crosstalk exists between these two hormonal axes; however, the mechanisms by which insulin and androgens may be reciprocally regulated are not well described. Androgen-dependant gene pathways regulate the growth and maintenance of both normal and malignant prostate tissue, and androgen-deprivation therapy (ADT) in patients exploits this dependence when used to treat recurrent and metastatic prostate cancer resulting in tumour regression. A major systemic side effect of ADT includes induction of key features of the metabolic syndrome and the consistent feature of hyperinsulinaemia. Recent studies have specifically identified a correlation between elevated insulin and high-grade PCa and more rapid progression to castrate resistant disease. This paper examines the relationship between insulin and androgens in the context of prostate cancer progression. Prostate cancer patients present a promising cohort for the exploration of insulin stabilising agents as adjunct treatments for hormone deprivation or enhancers of chemosensitivity for treatment of advanced prostate cancer.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.